1. Introduction {#sec1}
===============

Lung cancer is one of the most common tumor types in the U.S; with approximately 80% are NSCLC \[[@bib1],[@bib2]\]. Approximately 10--35% of NSCLC cases have causative mutations of the epidermal growth factor receptor gene, *EGFR* \[[@bib3], [@bib4], [@bib5]\]. While many forms of lung cancer are associated with a poor prognosis, drugs targeting mutated tyrosine kinase receptors are associated with clinical benefit and are widely used in cases positive for *EGFR* mutations \[[@bib6]\]. Appropriate molecular testing methods along with a thorough understanding of these tests' limitations are therefore relevant in facilitating the timely determination of NSCLC-related gene mutation status. The mutation information obtained can guide therapy choices in NSCLC patients, *i.e.,* the use of tyrosine kinase inhibitors (TKIs) \[[@bib7], [@bib8], [@bib9]\].

Allele-specific real-time PCR has been widely used in detecting *EGFR* "hotspot" mutations in cancerous tissues \[[@bib10], [@bib11], [@bib12], [@bib13], [@bib14], [@bib15]\]. *Therascreen*^*®*^ (Qiagen) is a FDA-approved real time PCR in vitro diagnostic (IVD) test that may be used to detect 21 *EGFR* mutations in exons 18, 19, 20, and 21 against a background of wild type genomic DNA \[[@bib16]\]. Advantages of the IVD include: (1) laboratory workflow is straightforward and rapid; (2) suboptimal quality genomic DNA, such as that extracted from FFPE tissues, can be used; and (3) variants with low allele fractions or that may be present in biopsies with low tumor content (\<10%) can reasonably be expected to be detected.

In recent years, NGS has been rapidly adopted in molecular diagnostic laboratories to detect gene mutations in cancers \[[@bib2],[@bib17]\] and can provide results by simultaneously interrogating hundreds of genomic loci. A small amount of input DNA is no longer a limiting factor in targeted library preparation for NGS-based interrogation. Consequently, when performing deep sequencing of targeted NGS panels, mutations may be detected at \~5% VAF. The capability of NGS to detect specific low-level mutations in tumors is important in determining targeted cancer therapy. We present data, based on instructive clinical cases, comparing allele-specific real-time PCR and NGS methods for detection of selected clinically important *EGFR* mutations.

2. Results {#sec2}
==========

Selected NSCLC specimens with low level *EGFR* mutations or late *therascreen*^®^ curves were used in this study. Shown in [Fig. 1](#fig1){ref-type="fig"}, the cancer hotspot NGS method revealed an *EGFR* c.2573T \> G (p.Leu858Arg) variant at 3% VAF with a read depth of 2672. The *therascreen*^®^ test was then performed on the same sample and this *EGFR* c.2573T \> G variant was also detected. This finding indicated that cancer hotspot NGS, similar to the *therascreen*^®^, accurately detects a common *EGFR* mutation at low VAF.Fig. 1The identification of *EGFR* c.2573T \> G (p.Leu858Arg) sequence change at 3% allele fraction by the cancer hotspot NGS (upper panel) and the *therascreen*^®^ (lower panel) tests.Fig. 1

The identification of a low level *EGFR* exon 19 deletion is shown in [Fig. 2](#fig2){ref-type="fig"}. The *EGFR* exon 19 deletion c.2240_2257delTAAGAGAAGCAACATCTC (p.Leu747_Pro753delinsSer) was accurately determined using the *therascreen*^®^ test. The observed deltaCt (7.62) is well within the reference range of the assay (\<9.06); this test result was therefore confidently reported despite the low allele frequency (see [Fig. 2](#fig2){ref-type="fig"}). We also performed the cancer hotspot NGS panel on this sample; this method did not detect the exon 19 deletion variant. Upon manual inspection of the aligned NGS reads, it appeared that this *EGFR* exon 19 deletion was present at 0.8% VAF (48/5872 reads), which is well below the LoD of cancer hotspot NGS \[[@bib17]\].Fig. 2An *EGFR* exon 19 deletion was accurately scored using the *therascreen*^®^ assay (upper panel). Manual review of the cancer hotspot NGS data revealed this deletion at 0.8% allele fraction (lower panel).Fig. 2

Besides detecting low level *EGFR* exon 19 deletions, *therascreen*^®^ detects *EGFR* T790M variants except when the real-time PCR curves occur much later in the amplification cycles. As shown in [Fig. 3](#fig3){ref-type="fig"}A, an *EGFR* exon 19 deletion and a late curve (Ct = 36.96) associated with *EGFR* T790M variant were observed with a *therascreen*^®^ assay. This late curve has a deltaCt value 8.25 that was considered outside the *therascreen*^®^ T790M reference range (\<6.38); as per the *therascreen*^®^ manual, such a late curve for the T790M variant cannot be accurately called. Thus, we investigated the identity of this *therascreen*^®^ finding using the cancer hotspot NGS panel \[[@bib17]\]. NGS analysis showed the presence of an *EGFR* exon 19 deletion and the T790M (c.2369C \> T) mutation at 19% and 5% VAFs, respectively ([Fig. 3](#fig3){ref-type="fig"}A). A similar *therascreen*^®^ case with a late *EGFR* T790M amplification curve (Ct = 32.96) and exon 19 deletion are shown in [Fig. 3](#fig3){ref-type="fig"}B. This late curve has a deltaCt value 7.61 that is greater than the *therascreen*^®^ T790M reference cut-off (\<6.38). Again, we were able to detect the T790M (c.2369C \> T) mutation on the cancer hotspot NGS panel at 2% VAF. These NGS results demonstrate that late *therascreen*^®^ curves of T790M represent true positive findings.Fig. 3**(A)** A suspected *EGFR* T790M variant (Ct = 36.96) was not scored within the *therascreen*^®^ reference range (upper panel). Alternatively, cancer hotspot NGS accurately called this variant at 5% allele fraction (lower panel). **(B)** Another example of a late *EGFR* T790M *therascreen*^®^ curve (Ct = 32.96) resulted in the deltaCt not within the reference range (upper panel). Cancer hotspot NGS identified this variant at 2% allele fraction (lower panel). Note: the *EGFR* exon 19 deletions are not shown in the NGS pileup results.Fig. 3

3. Discussion {#sec3}
=============

*Therascreen*^®^ is a sensitive assay to detect some clinically important *EGFR* mutations. We show here that *therascreen*^®^ can accurately identify low level *EGFR* L858R (3%) and exon 19 deletion (1%) variants ([Fig. 1](#fig1){ref-type="fig"}, [Fig. 2](#fig2){ref-type="fig"}). It is worth noting that the current cancer hotspot NGS panel was not designed to identify \<2% VAF in certain *EGFR* hotspots, such as exon 19 deletions. In this regard, the *therascreen*^®^ test has a favorable LoD at the *EGFR* exon 19 locus. However, the claimable LoDs on the *therascreen*^®^ user manual vary among the interrogated *EGFR* mutation hotspots. While the LoD of exon 19 deletions could be as low as 0.81%, the LoDs of exon 20 T790M (c.2369C \> T) and exon 18 G719A (c.2156G \> C) are reported higher at 17.5% and 32.5% VAFs, respectively.

Since the presence of T790M variant is an indication of TKI resistance, the ability to identify low VAF at this locus is essential in determining drug administration and monitoring therapeutic response. The importance of detecting low level T790M mutations has been stated in the 2018 College of American Pathology molecular testing guideline for selecting NSCLC patients for targeted TKI therapies \[[@bib18]\]. The cases described here have late T790M Ct curves that were outside the operating range of the assay, indicating that *therascreen*^®^ does not detect the T790M mutation when present at low levels and an alternate method should be used to screen for or confirm low level T790M mutation ([Fig. 3](#fig3){ref-type="fig"}). In contrast, the in-house developed cancer hotspot NGS assay can detect T790M (c.2369C \> T) variant at near 2% VAF.

An allele-specific real-time PCR method, such as *therascreen*^®^, indirectly reveals a gene\'s mutation status. It assumes that the identified variants have the same sequence compositions as the interrogating allele-specific primers or probes. This assumption is generally true for most of *EGFR* mutation hotspots, but there are important exceptions such as the complex cases presented here. As shown in [Fig. 4](#fig4){ref-type="fig"}, *therascreen*^®^ called the *EGFR* exon 19 deletion without revealing the presence of a 10-base and two single-base deletions. Sanger sequencing was performed and confirmed the NGS result (data not shown). Since the 10-base and the two individual nucleotide deletions occurred on the same sequence read with the same VAFs, these nucleotide changes should be reported as concurrent events and represent a complex exon 19 deletion (c.2239_2264delins14, p.Leu747_Ala755delinsGlnHisLeuArgSer). Of interest, if the sequence changes were not concurrent, each of the three separate deletions would result in a loss-of-function, frame-shift gene product that would not explain the oncogenic character of an *EGFR* exon 19 variant. Only when all three events occur within the same allele will the deletions create a 12-base, in-frame *EGFR* exon 19 deletion at this region. For this case, regardless as to whether the exact sequence alteration was determined, there would be no impact on patient care because both test platforms consistently called the *EGFR* exon 19 deletion and suggest TKI-based therapies for the patient. Although *therascreen*^®^ did report the sequence changes as an *EGFR* exon 19 deletion, the complexity of the allele was not identified. By analogy, other *EGFR* sequence alterations may be inaccurately classified using the *therascreen*^®^ method (see below).Fig. 4A complex *EGFR* exon 19 sequence change. The *therascreen*^®^ result indicated an *EGFR* exon 19 deletion (upper panel). Cancer hotspot NGS revealed this *EGFR* exon 19 sequence change consists of a 10-base and two individual single-base deletions (lower panel).Fig. 4

Another example of the importance of accurately revealing the sequence changes of a gene mutation is shown in [Fig. 5](#fig5){ref-type="fig"}. This NSCLC specimen has two consecutive missense variants (c.2239_2240delinsCC, p.Leu747Pro, Sanger sequencing confirmed) that should be called as insertion/deletion (indel), but were interpreted by *therascreen*^®^ test as an *EGFR* exon 19 deletion event. This difference in variant classification could potentially affect the patient\'s clinical management; the calling of an *EGFR* exon 19 deletion indicates that a tumor is likely TKI sensitive, while the calling of a two-base indel results in only one amino acid alteration which is less responsive to TKI treatment \[[@bib19], [@bib20], [@bib21]\].Fig. 5An unusual *EGFR* exon 19 sequence change was determined as deletion by *therascreen*^®^ (upper panel). The cancer hotspot NGS revealed the sequence change involves two consecutive missense variants (lower panel).Fig. 5

In summary, we have shown examples of real-time PCR (*therascreen*^®^) and hotspot NGS assays that are able to identify low VAF somatic mutations, despite the LoDs of both platforms varying among different genomic loci. Since it is not cost-effective to test the same sample on two different assay platforms, we suggest those laboratories who routinely run *EGFR therascreen*^®^ test should have an alternative approach to confirm the findings of late PCR curves. Moreover, for those patients who appear to be resistant to TKI therapy despite having an exon 19 mutation, additional testing should be considered to ensure an accurate classification of the *EGFR* mutation. For those laboratories that perform cancer hotspot NGS tests, a careful determination of the LoDs during test validation at multiple *EGFR* loci will reduce false-negative calls. Furthermore, having an alternative method such as *therascreen*^®^ may be useful when there is limited amount of sample available to confirm the absence of a mutation in *EGFR*.

4. Methods {#sec4}
==========

4.1. Tumor samples and DNA extraction {#sec4.1}
-------------------------------------

Genomic DNA was extracted from tumor specimens collected from NSCLC patients as previously described \[[@bib17],[@bib22],[@bib23]\]. Cytology specimens were briefly kept in PreservCyt solution then were manually extracted according to the Gentra Puregene DNA Extraction Kit (Qiagen, Hilden, Germany) user\'s manual. DNA from FFPE tissue specimens was extracted using Maxwell^®^ DNA FFPE Kit (Promega, Madison, WI) in an automated fashion. Purified genomic DNA was stored at 4 °C.

4.2. Cancer hotspot panel library preparation, sequencing, and data analysis {#sec4.2}
----------------------------------------------------------------------------

Cancer hotspot NGS library preparation was performed as previously described \[[@bib17]\]. The sequencing data were aligned to human genome build 19 (HG19) and variants in *EGFR* were identified using NextGENe Software (Soft Genetics, State College, PA). The Integrative Genomics Viewer (IGV) was used to visually inspect the quality of read alignment and variant calls. A quality score of Q30 was used as filtering criteria to determine the sequence read quality. For a given sample, the minimum coverage requirement of targeted regions was 100X. Variants with VAFs as low as 2% may be identified.

4.3. therascreen^®^ {#sec4.3}
-------------------

The *EGFR* real-time PCR test (*therascreen*^®^) was performed as previously described \[[@bib24]\]. *therascreen*^®^ *EGFR* RGQ PCR Kit (Qiagen) \[[@bib14]\] is an FDA approved real-time PCR-based in vitro diagnostic test that was used to cross-check the variant findings from the NGS-based, laboratory-developed AmpliSeq Cancer Hotspot Panel. The PCR test consists of eight separate PCR amplification mixes; amplification occurs in the Rotor-Gene Q MDx instrument. *therascreen*^®^ can be used to detect common *EGFR* mutations, *e.g.,* T790M, L858R, L861Q, G719X, S768I, various exon 19 deletions, and exon 20 insertions.

4.4. Sample selection {#sec4.4}
---------------------

Fifty-four NSCLC specimens previously analyzed using *EGFR therascreen*^®^ test were analyzed by the NGS-based study. These specimens included variants identified in late *therascreen*^®^ PCR cycles, and equivocal variant calls that occurred outside the real-time PCR reference range. Four of the cases with low VAF and late PCR curves are shown in this manuscript. Additionally, two NSCLC specimens with complex and consecutive *EGFR* sequence changes ([Fig. 4](#fig4){ref-type="fig"}, [Fig. 5](#fig5){ref-type="fig"}) identified in the NGS test were further interrogated using *therascreen*^®^ and shown. Since deep sequencing had been performed using the cancer hotspot NGS panel, clinically significant loci were read at \>1000 reads. Variants with \<5% VAF detected with NGS were evaluated further by manually reviewing the read qualities at each of the *EGFR* loci.
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